« Previous article
Cleanroom Microbiolo...

1st March 2021  Product update: rapidmicrobiology staff writer

ECDC & Eurofins Genomics Partner to Provide Rapid SARS-CoV-2 Variant Surveillance

The European Centre for Disease Prevention and Control (ECDC) has begun work with Eurofins Genomics with the objective to monitor mutations across European countries.

The EU/EEA Member States are in the phase of increasing both their sequencing capacities and capabilities to set up a robust surveillance system that allows for the detection and monitoring of variant viruses.

To support this goal, Eurofins Genomics will provide additional sequencing capacity using ARTIC Next Generation Sequencing (NGS) technology. This includes the ARTIC NGS Oligo mix that is synthesized by Eurofins Genomics’ Synthesis branch. The service and oligo mix are based on a protocol by the ARTIC consortium, which is used for SARS-CoV-2 sequencing worldwide. 

The ARTIC approach utilises an oligo pool for multiplexed PCR amplification of the complete viral genome. Eurofins Genomics optimised the formulation of the oligo pool achieving the highest performance and best-in-class uniformity of coverage for the full-length viral genome.

Eurofins Genomics’ sophisticated bioinformatic pipeline assembles and compares the resulting contiguous full-length SARS-CoV-2 isolate sequences and delivers a report for conclusive interpretation.

More information on this new “SARS-CoV-2 Full-length Genome Sequencing” service can be found here.

The full coronavirus product range offered by Eurofins Genomics Europe, including SARS-CoV-2 qPCR assays or SARS-CoV-2 plasmid controls, can be found here.



Date Published: 1st March 2021

Source article link: View

Note: This content has been edited by a rapidmicrobiology staff writer for style and content.

View full company details